Drugs / sensitized T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05235607 | Mar 2022 → Jun 2023 | carcinoma, colorectal cancer, melanoma, urinary bladder cancer | Sichuan University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sensitized T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05235607 ↗ |
| Modality | Cell therapy | “sensitized T cells” NCT05235607 ↗ |
| Route | Subcutaneous | “subcutaneous administration” NCT05235607 ↗ |